CERTAIN INFORMATION IN THIS EXHIBIT IDENTIFIED BY [***] IS CONFIDENTIAL AND HAS BEEN EXCLUDED BECAUSE IT (I) IS NOT MATERIAL AND (II) THE REGISTRANT CUSTOMARILY AND ACTUALLY TREATS THAT INFORMATION AS PRIVATE OR CONFIDENTIAL. LICENSING & DISTRIBUTION...Licensing & Distribution Agreement • March 4th, 2022 • Altamira Therapeutics Ltd. • Pharmaceutical preparations
THIS LICENSING & DISTRIBUTION AGREEMENT (this “Agreement”) is made and entered into on February 28, 2022 (the “Effective Date”), by and between Altamira Medica Ltd., Bahnhofstrasse 21, 6300 Zug, Switzerland, a company organized under the laws of Switzerland (hereinafter referred to as “Altamira”), and Nuance Pharma Limited, with its registered address at Unit 417, 4/F, Lippo Centre Tower Two, No. 89 Queensway Admiralty, Hong Kong, a company organized under the laws of Hong Kong (hereinafter referred to as “Nuance”) (Altamira and Nuance both a “Party” and jointly the “Parties”).
Altamira Therapeutics and Nuance Pharma Enter into Exclusive Licensing and Distribution Agreement for Bentrio™ in China and Additional Asian MarketsExclusive Licensing and Distribution Agreement • March 4th, 2022 • Altamira Therapeutics Ltd. • Pharmaceutical preparations
Hamilton, Bermuda, March 4, 2022 – Altamira Therapeutics Ltd. (NASDAQ: CYTO), a company dedicated to addressing unmet medical needs through RNA therapeutics, allergy and viral infection protection, and inner ear therapeutics, announced today that it has entered into an exclusive licensing and distribution agreement (the “Agreement”) for Bentrio™, its nasal spray for protection against airborne viruses and allergens, with Nuance Pharma Ltd. (“Nuance”) in Chinese Mainland, Hong Kong, Macau and South Korea (the “Territory”).
